Drug Patent Watch

JULY 24, 2025

At the forefront of this movement is DrugPatentWatch, a powerful tool that's providing unprecedented visibility into the world of drug patents. Join the conversation and learn how DrugPatentWatch is revolutionizing the way we think about drug development and access. Read the full story here: [link] "

Research

Drug Patent Watch

DECEMBER 11, 2024

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

Pharmaceutical Companies

Crown Bioscience

AUGUST 5, 2025

Organoids are cultured cell structures that mimic the complexities of human organs, allowing researchers to study them under conditions that closely replicate real biological environments. For decision-makers in the pharmaceutical and biotech industries, organoids represent a key innovation extending beyond existing in vitro models.

Drug Development

Crown Bioscience

AUGUST 5, 2025

Organoids are cultured cell structures that mimic the complexities of human organs, allowing researchers to study them under conditions that closely replicate real biological environments. For decision-makers in the pharmaceutical and biotech industries, organoids represent a key innovation extending beyond existing in vitro models.

Drug Development

Alta Sciences

JULY 31, 2025

This partnership combines Altasciences’ comprehensive early-phase drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Drug Development

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. What is a Drug Patent?

Drugs

Drug Patent Watch

FEBRUARY 12, 2025

Accelerating Generic Drug Development: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drug development. The generic drug development process involves several stages, from patent research to regulatory approvals.

Drug Development

PPD

DECEMBER 16, 2024

Our annual look at the state of the drug development industry highlights a dual set of challenges complicating progress. Rising costs have become a persistent challenge for drug developers, driven by a combination of internal and external pressures that have intensified in recent years.

Drug Development

Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Research using NHPs often requires detailed justification, approval by ethics committees and regular inspections.

Drug Research

Drug Patent Watch

DECEMBER 12, 2024

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing

Drug Patent Watch

FEBRUARY 13, 2025

The Unsung Heroes of Generic Drug Development: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development

Drug Target Review

JUNE 6, 2025

This dual role enables him to bridge research and clinical practice, ensuring scientific innovation is directly informed by patient care. “As At RadioMedix, he helps drive strategy, identifies promising candidates and isotopes, and oversees the development of both diagnostic and therapeutic agents – often in the form of theranostic pairs.

Therapies

Drug Target Review

OCTOBER 30, 2024

Creating replicas of organs in vitro has been a goal of researchers for over a century. 1 This early work laid the foundation for a century of research on finding the optimal conditions for growing parts of organs in in vitro cultures, testing their functions and even mimicking many diseases.

Treatment

The Pharma Data

JUNE 24, 2025

This dual-pronged approach allows Revolution Medicines to access capital tailored to its evolving needs without relinquishing equity or ceding commercial rights to a larger pharmaceutical partner. Source link

Drug Development

The Pharma Data

JUNE 13, 2025

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. MRI) and Astellas Pharma Inc.

Research

Drug Target Review

AUGUST 12, 2025

In the race to accelerate drug discovery, artificial intelligence (AI) has already proven itself to be adept in areas like target identification, virtual screening and molecular generation. Case example: better molecules, faster Imagine a team discovers a molecule with excellent in vitro potency and drug-like properties.

Drugs

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease

Conversations in Drug Development Trends

OCTOBER 29, 2024

By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Why Is There an Increase in Patient-Led Rare Disease Research?

Clinical Research

Fierce BioTech

NOVEMBER 22, 2024

AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future.

Drug Development

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. In addition to tackling the complexities of endogenous molecule measurement, HRMS is also effective in evaluating excipients, potential drug metabolites, and drug-drug interactions.

International

Drug Target Review

JUNE 16, 2025

Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology. References [1].

Drugs

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. Tags Bioanalysis Preclinical Research Weight 15 This can result in failed runs and wasted reagents.

Pharmacokinetics

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools

The Premier Consulting Blog

APRIL 13, 2025

On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ 2] An overview of the 3Rs The FDA and other global regulatory health authorities have long embraced the 3Rs of animal research (replace, reduce, and refine).

Animal Testing

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., and Shanghai Fosun Pharmaceutical (Group) Co.,

Therapies

The Pharma Data

JUNE 18, 2025

Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D., He holds a B.A.

RNA

Drug Target Review

JULY 10, 2025

These core ADMET properties are fundamental to drug development across the industry, making them well-suited for pre-competitive collaboration. A fundamental shift in early-stage research With tightened funding and rising global competition, Haimson notes that demand for Inductive Bio’s platform is only growing.

Metabolic Stability

Drug Target Review

AUGUST 6, 2025

A validated target in cardiovascular disease, new research from Esperion Therapeutics suggests that ACLY could also play a role in liver disease – specifically, primary sclerosing cholangitis (PSC). The approach could offer a new angle on a disease that has thus far resisted most conventional drug development strategies.

Therapies

The Pharma Data

JUNE 24, 2025

In this context, the USP’s mAb reference standards offer pharmaceutical manufacturers a critical benchmark. These standards are widely recognized by regulatory agencies such as the FDA and EMA for use in analytical method development, validation, and quality control. Senior Vice President of Global Biologics at USP.

Therapies

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry.

Treatment

Alta Sciences

MARCH 4, 2025

The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. I have spent the better part of my career working to make drugs safer.

Clinical Trials

Drug Target Review

DECEMBER 9, 2024

Since its launch, AlphaFold has accurately predicted the structure of over 200 million proteins and been used by more than 2 million researchers globally. Despite its recent development, AlphaFold2 has already been applied in numerous studies across biology and medicine.

Engineering

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.

Clinical Pharmacology

DrugBank

JUNE 18, 2025

Drug development is a complex and highly regulated process. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global counterparts, set rigorous standards to ensure that drugs are safe, effective, and high-quality. Regulatory agencies, such as the U.S.

Drug Development

Drug Target Review

AUGUST 8, 2025

Partnering with experienced contract development and manufacturing organisations (CDMOs) can help developers navigate these complexities, accelerate development timelines, and ensure readiness for scalable, cGMP-compliant manufacturing. 3 As these therapies evolve, so too must the tools and processes used to develop them.

Engineering

Drug Target Review

MARCH 4, 2025

Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. The research demonstrated that obesity is not one disease, but many; each of which should be treated with different interventions, says Bagnall. These individuals respond four times better to GLP-1 medications.

Therapies